首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   715911篇
  免费   49388篇
  国内免费   1357篇
耳鼻咽喉   9238篇
儿科学   23420篇
妇产科学   17753篇
基础医学   111767篇
口腔科学   20383篇
临床医学   64489篇
内科学   136683篇
皮肤病学   16348篇
神经病学   50154篇
特种医学   26317篇
外国民族医学   76篇
外科学   106103篇
综合类   14875篇
现状与发展   2篇
一般理论   160篇
预防医学   51738篇
眼科学   16513篇
药学   54563篇
  3篇
中国医学   2364篇
肿瘤学   43707篇
  2021年   5633篇
  2018年   8065篇
  2017年   6253篇
  2016年   7009篇
  2015年   7717篇
  2014年   10472篇
  2013年   15644篇
  2012年   20981篇
  2011年   22012篇
  2010年   12974篇
  2009年   12177篇
  2008年   20436篇
  2007年   21941篇
  2006年   22375篇
  2005年   20909篇
  2004年   20433篇
  2003年   19391篇
  2002年   18936篇
  2001年   36615篇
  2000年   37208篇
  1999年   30710篇
  1998年   8013篇
  1997年   6772篇
  1996年   7062篇
  1995年   6691篇
  1994年   6174篇
  1993年   5678篇
  1992年   23199篇
  1991年   23157篇
  1990年   22520篇
  1989年   22285篇
  1988年   20242篇
  1987年   19609篇
  1986年   18642篇
  1985年   17488篇
  1984年   12820篇
  1983年   10813篇
  1982年   5968篇
  1979年   11619篇
  1978年   8178篇
  1977年   6880篇
  1976年   6642篇
  1975年   7322篇
  1974年   8544篇
  1973年   8193篇
  1972年   7701篇
  1971年   7170篇
  1970年   6917篇
  1969年   6344篇
  1968年   5820篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
81.
82.
83.
10 patients with CLL and 2 with CML were treated with gradually increasing doses of 1 alpha(OH)D3, up to 4 micrograms daily during 6 wk. 3 patients with preleukemia and 1 with myelofibrosis were treated with 2 micrograms daily of 1 alpha(OH)D3 for a prolonged period up to 17 wk. The treatment with 1 alpha (OH)D3 did not result in changes of disease parameters in any of the patients under study. Receptor studies for 1,25(OH)2D3 were performed in 8 CLL patients and revealed only 1 patient with increased specific receptor binding capacity. The maximum tolerable dose of 1 alpha(OH)D3 varied individually, but was in the range of 2-4 micrograms daily.  相似文献   
84.
Biliopancreatic diversion is a very effective method for weight reduction. In some instances it is too effective and needs to be revised.  相似文献   
85.
86.
In 1983, 1623 primary and secondary schoolchildren took part in a health survey which was organized by the Busselton Population Studies Group. Age, sex, weight, height and country of birth were recorded for each child. Where possible, the country of birth of parents and the occupation of the father were extracted from previous Busselton surveys of adults. Compared with Perth schoolchildren, the difference in the attained weight and height of Busselton children at any age was small. This was so even though the two communities differ in location (rural compared with metropolitan), in ethnic origin (mainly British compared with diverse origins) and, probably, in social-rank distribution. Data from the two communities showed that a similar small secular increase in height had occurred since 1970/1971. This increase averaged at 1.2 cm for children at each year of age in Busselton and 1.5 cm to 1.6 cm for children in Perth.  相似文献   
87.
88.
A novel approach for modelling the biological activity of organic molecules, which requires simultaneous consideration of the influence of all factors (topological, steric, hydrophobic, and electronic) that determine the bioactivity, is used to study the interaction of a series of benzoates with anti-p-(p'-azophenylazo)benzoate antibody. The results obtained suggest that this biological interaction proceeds by a two-step stereospecific mechanism. The first step requires a geometrical correspondence between the benzoates and the cavity in the biomacromolecule, which enables the pharmacophore to come into close contact with the receptor. The second step is the orbitally controlled electronic interaction between the active parts of the benzoates and the antibody. The electronic interaction results from pi-charge transfer from the pharmacophore to the biomacromolecule and from the formation of pi-complexes. A proposed mathematical model for this biological interaction exhibits some statistical advantages over existing models.  相似文献   
89.
90.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号